[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349150-105":59,"doc-detail-349150-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","subgroup-performance-of-a-commercial-digital-breast-tomosynthesis-model-for-breast-cancer-detection-received-18-march-2025","Subgroup performance of a commercial digital breast tomosynthesis model for breast cancer detection - Received 18 March 2025","","AI models for breast cancer screening show promise, yet detailed subgroup evaluations are often missing, limiting understanding of strengths and weaknesses. This study performs a granular assessment of a commercial AI cancer detection model on digital breast tomosynthesis (DBT) using a retrospective cohort of 167,860 screening exams. Cancer detection distinguishes screen-detected cancers from negatives and evaluates performance across demographic, imaging, and pathologic subgroups.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/subgroup-performance-of-a-commercial-digital-breast-tomosynthesis-model-for-breast-cancer-detection-received-18-march-2025/349150/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/subgroup-performance-of-a-commercial-digital-breast-tomosynthesis-model-for-breast-cancer-detection-received-18-march-2025/349150.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What gap does the study address about AI breast cancer models?","Question",{"text":113,"@type":114},"The study targets the lack of detailed subgroup evaluations that clarify where models perform well or poorly across demographics, imaging, and pathology.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the commercial DBT AI model evaluated?",{"text":118,"@type":114},"Performance was measured on a retrospective cohort of 167,860 screening exams, stratifying results between screen-detected cancers and negative exams across multiple subgroup types.",{"name":120,"@type":111,"acceptedAnswer":121},"Which findings indicate stronger vs weaker model performance?",{"text":122,"@type":114},"The study reports lower performance for in-situ cancers, calciﬁcations, and dense breast tissue, while masses and architectural distortions show higher performance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349150,1790534626,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Article [https://doi.org/10.1038/s41467-026-70637-3](https://doi.org/10.1038/s41467-026-70637-3)  \nSubgroup performance of a commercial digital breast tomosynthesis model for breast cancer detection  \nReceived: 18 March 2025  \n\n| Accepted: 24 February 2026 |\n| --- |\n| |\n| Check for updates |\n\nBeatrice Brown-Mulry 1,5, Rohan Satya Isaac 1,5, Sang Hyup Lee 2, Ambika Seth2, KyungJee Min2, Theo Dapamede1, Frank Li1, Aawez Mansuri1, MinJae Woo3, Christian Allison Fauria-Robinson4, Bhavna Paryani4,  \nJudy Wawira Gichoya 1 & Hari Trivedi1   \nAI models show potential to improve breast cancer screening, however detailed subgroup evaluations to uncover the strengths and weaknesses of models are lacking. This study presents a granular evaluation of a commercial AI model for cancer detection on digital breast tomosynthesis (DBT) on a retrospective cohort of 167,860 screening exams in female patients. Performance in distinguishing screen detected cancers (1,368 exams) from negative exams (166,387 exams) is stratiﬁed across demographic, imaging, and pathologic subgroups to identify disparities. The overall AUROC is 0.91 and sensitivity is 0.73 with robust performance across demographics. In-situ cancers (AUROC: 0.85, sensitivity: 0.55), calciﬁcations (AUROC: 0.80, sensitivity: 0.66), and dense breast tissue (AUROC: 0.88, sensitivity: 0.63) are associated with lower performance, while masses (AUROC: 0.93, sensitivity: 0.85) and architectural distortions (AUROC: 0.90, sensitivity: 0.83) are associated with higher performance. These results highlight the need for detailed evaluations and vigilance in adopting new clinical tools.  \nBreast cancer is the most common type of cancer in women and causes 42,000 deaths each year in the United States1. Screening mammography has historically been associated with a 38-48% reduction in breast cancer mortality through early detection of abnormalities and enabling earlier treatment2–4, although recent analyses of contemporary observational data suggest that the observed protective effects may not be solely attributable to screening itself5. The Breast Imaging Reporting and Data System (BI-RADS), developed by the American College of Radiology, is a standardized framework used to categorize breast imaging ﬁndings and guide management. BI-RADS includes both an overall assessment score (ranging from 0 to 6) and speciﬁc lesion descriptors such as mass shape, margin, calciﬁcation morphology, and asymmetry type. Each BI-RADS category corresponds to a recommended clinical action: for example, Category 1 (negative) and 2 (benign) require routine screening, Category 3  \n(probably benign) suggests short-interval follow-up, and Categories 4 and 5 (suspicious and highly suggestive of malignancy) prompt biopsy6. Despite this, the sensitivity and speciﬁcity of 2D screening mammography remain around 86.9% and 88.9% resulting in unnecessary recalls and biopsies, as well as missing cancers7. Earlier data from the Breast Cancer Detection Demonstration Project(BCDDP) also showed age-related sensitivities of 90% for women under 50 and 95% for women 50 and older8.  \nOver the past two decades, digital breast tomosynthesis (DBT) has emerged as an advanced imaging modality designed to address the limitations of 2D mammography. DBT provides pseudo-threedimensional imaging of the breast by reconstructing multiple 2D projections into image slices and can improve speciﬁcity by reducing the masking effect of overlapping tissues9,10. These advantages have led to widespread adoption of the technology since its FDA approval in  \n1HITI Lab, Emory University, Atlanta, GA, USA. 2Lunit, Seoul, South Korea. 3Clemson University, Clemson, SC, USA. 4Emory University, Atlanta, GA, USA. 5These authors contributed equally: Beatrice Brown-Mulry, Rohan Satya Isaac. e-mail: [hari.trivedi@emory.edu](hari.trivedi@emory.edu)  \n201111, however research has demonstrated weaknesses in some areas compared to conventional mammography. These include the increase","cbCaibU5aVkGeiz5","https://ap.wps.com/l/cbCaibU5aVkGeiz5","pdf",1596722,12,"English","# Study purpose and rationale\n# Dataset and evaluation approach\n# Overall detection performance\n# Subgroup performance by cancer type and imaging factors\n# Clinical implications for adoption and monitoring","[{\"question\":\"What gap does the study address about AI breast cancer models?\",\"answer\":\"The study targets the lack of detailed subgroup evaluations that clarify where models perform well or poorly across demographics, imaging, and pathology.\"},{\"question\":\"How was the commercial DBT AI model evaluated?\",\"answer\":\"Performance was measured on a retrospective cohort of 167,860 screening exams, stratifying results between screen-detected cancers and negative exams across multiple subgroup types.\"},{\"question\":\"Which findings indicate stronger vs weaker model performance?\",\"answer\":\"The study reports lower performance for in-situ cancers, calciﬁcations, and dense breast tissue, while masses and architectural distortions show higher performance.\"}]","Subgroup performance of a commercial digital breast tomosynthesis model for breast cancer detection - Received 18 March 2025 | PDF",1790081977,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d88dc26a5b7f81be45e54fc92e45cd3.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27567041c101ba0c3b9b632cb15bfc5d.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a87673a504433da96969a96689c153cf.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd0c655ce80f7b46b3cd6599792d486d.webp",980,1301]